DGIdb - DPYD Gene Record

DPYD 1806 Druggable GenomeClinically Actionable

Alternate Names:

1806
DIHYDROPYRIMIDINE DEHYDROGENASE
DPYD
DHP
DHPDHASE
DPD
612779
3012
ENSG00000188641
OTTHUMG00000039683
1526
Q12882
DIHYDROPYRIMIDINE DEHYDROGENASE [NADP+] PRECURSOR (EC 1.3.1.2) (DPD) (DHPDHASE) (DIHYDROURACIL DEHYDROGENASE) (DIHYDROTHYMINE DEHYDROGENASE). [SOURCE:UNIPROT/SWISSPROT;ACC:Q12882]
PA145
Dihydrothymine dehydrogenase
T75890
DYPD
Dihydropyrimidine dehydrogenase [NADP(+)]

Gene Info:

Target Class	Enzymes
Target Subclass	EC:1.3.1.2
Human Readable Name	DRUGGABLE GENOME
Gene Biotype	PROTEIN_CODING

(7 More Sources)

Gene Categories: Category Details

DRUGGABLE GENOME
CLINICALLY ACTIONABLE
ENZYME

Publications:

Stepanova et al., 2005, [Thymidylate synthase, thymidine phosphorylase and dihydropyrimidine dehydrogenase expression in soft-tissue sarcoma versus capecitabine potential]., Vopr Onkol
Caudle et al., 2013, Clinical Pharmacogenetics Implementation Consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing., Clin. Pharmacol. Ther.
Van Kuilenburg AB et al., 1997, Heterozygosity for a point mutation in an invariant splice donor site of dihydropyrimidine dehydrogenase and severe 5-fluorouracil related toxicity., Eur J Cancer
Vreken P et al., 1997, Dihydropyrimidine dehydrogenase (DPD) deficiency: identification and expression of missense mutations C29R, R886H and R235W., Hum Genet
Holopainen I et al., 1997, Partial epilepsy in a girl with a symptom-free sister: first two Finnish patients with dihydropyrimidine dehydrogenase deficiency., J Inherit Metab Dis
O'Donnell PH et al., 2020, Clinical evaluation of germline polymorphisms associated with capecitabine toxicity in breast cancer: TBCRC-015., Breast Cancer Res Treat
Lampropoulou DI et al., 2020, Fluoropyrimidine-induced toxicity and DPD deficiency.. A case report of early onset, lethal capecitabine-induced toxicity and mini review of the literature. Uridine triacetate: Efficacy and safety as an antidote. Is it accessible outside USA?, J Oncol Pharm Pract
Iachetta F et al., 2019, The clinical relevance of multiple DPYD polymorphisms on patients candidate for fluoropyrimidine based-chemotherapy. An Italian case-control study., Br J Cancer
Del Re M et al., 2019, DPYD6 plays an important role in fluoropyrimidine toxicity in addition to DPYD2A and c.2846A>T: a comprehensive analysis in 1254 patients., Pharmacogenomics J
Madi A et al., 2018, Pharmacogenetic analyses of 2183 patients with advanced colorectal cancer; potential role for common dihydropyrimidine dehydrogenase variants in toxicity to chemotherapy., Eur J Cancer
Tariq Z et al., 2018, Capecitabine Toxicity and Dihydropyrimidine Dehydrogenase Deficiency., Am J Ther
Duley JA et al., 2018, Preliminary Evidence for Enhanced Thymine Absorption: A Putative New Phenotype Associated With Fluoropyrimidine Toxicity in Cancer Patients., Ther Drug Monit
Nahid NA et al., 2018, DPYD*2A and MTHFR C677T predict toxicity and efficacy, respectively, in patients on chemotherapy with 5-fluorouracil for colorectal cancer., Cancer Chemother Pharmacol
Zurayk M et al., 2019, Successful use of uridine triacetate (Vistogard) three weeks after capecitabine in a patient with homozygous dihydropyrimidine dehydrogenase mutation: A case report and review of the literature., J Oncol Pharm Pract
Henricks LM et al., 2018, Capecitabine-based treatment of a patient with a novel DPYD genotype and complete dihydropyrimidine dehydrogenase deficiency., Int J Cancer
Nie Q et al., 2017, Quantitative Contribution of rs75017182 to Dihydropyrimidine Dehydrogenase mRNA Splicing and Enzyme Activity., Clin Pharmacol Ther
Meulendijks D et al., 2017, Pharmacogenetic variants associated with outcome in patients with advanced gastric cancer treated with fluoropyrimidine and platinum-based triplet combinations: a pooled analysis of three prospective studies., Pharmacogenomics J
Roberto M et al., 2017, Evaluation of 5-fluorouracil degradation rate and Pharmacogenetic profiling to predict toxicity following adjuvant Capecitabine., Eur J Clin Pharmacol
Milano G, 2016, Highlight on DPYD gene polymorphisms and treatment by capecitabine (.)., Scand J Clin Lab Invest Suppl
González-Perera I et al., 2017, 5-fluorouracil toxicity in the treatment of colon cancer associated with the genetic polymorphism 2846 A>G (rs67376798)., J Oncol Pharm Pract
Zhao XQ et al., 2016, DPYD gene polymorphisms are associated with risk and chemotherapy prognosis in pediatric patients with acute lymphoblastic leukemia., Tumour Biol
Kuilenburg ABPV et al., 2016, Phenotypic and clinical implications of variants in the dihydropyrimidine dehydrogenase gene., Biochim Biophys Acta
Boige V et al., 2016, DPYD Genotyping to Predict Adverse Events Following Treatment With Fluorouracil-Based Adjuvant Chemotherapy in Patients With Stage III Colon Cancer: A Secondary Analysis of the PETACC-8 Randomized Clinical Trial., JAMA Oncol
Meulendijks D et al., 2015, Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data., Lancet Oncol
Thomas F et al., 2016, Genotyping of a family with a novel deleterious DPYD mutation supports the pretherapeutic screening of DPD deficiency with dihydrouracil/uracil ratio., Clin Pharmacol Ther
Gentile G et al., 2016, Genotype-phenotype correlations in 5-fluorouracil metabolism: a candidate DPYD haplotype to improve toxicity prediction., Pharmacogenomics J
Toffoli G et al., 2015, Clinical validity of a DPYD-based pharmacogenetic test to predict severe toxicity to fluoropyrimidines., Int J Cancer
Dhelens C et al., 2016, Lethal 5-fluorouracil toxicity in a colorectal patient with severe dihydropyrimidine dehydrogenase (DPD) deficiency., Int J Colorectal Dis
Joerger M et al., 2015, Germline TYMS genotype is highly predictive in patients with metastatic gastrointestinal malignancies receiving capecitabine-based chemotherapy., Cancer Chemother Pharmacol
Sistonen J et al., 2014, Predicting 5-fluorouracil toxicity: DPD genotype and 5,6-dihydrouracil:uracil ratio., Pharmacogenomics
Froehlich TK et al., 2015, Clinical importance of risk variants in the dihydropyrimidine dehydrogenase gene for the prediction of early-onset fluoropyrimidine toxicity., Int J Cancer
Cai X et al., 2014, The role of IVS14+1 G > A genotype detection in the dihydropyrimidine dehydrogenase gene and pharmacokinetic monitoring of 5-fluorouracil in the individualized adjustment of 5-fluorouracil for patients with local advanced and metastatic colorectal cancer: a preliminary report., Eur Rev Med Pharmacol Sci
Teh LK et al., 2013, Potential of dihydropyrimidine dehydrogenase genotypes in personalizing 5-fluorouracil therapy among colorectal cancer patients., Ther Drug Monit
Terrazzino S et al., 2013, DPYD IVS14+1G>A and 2846A>T genotyping for the prediction of severe fluoropyrimidine-related toxicity: a meta-analysis., Pharmacogenomics
Saif MW, 2013, Dihydropyrimidine dehydrogenase gene (DPYD) polymorphism among Caucasian and non-Caucasian patients with 5-FU- and capecitabine-related toxicity using full sequencing of DPYD., Cancer Genomics Proteomics
Magnani E et al., 2013, Fluoropyrimidine toxicity in patients with dihydropyrimidine dehydrogenase splice site variant: the need for further revision of dose and schedule., Intern Emerg Med
Zhang XP et al., 2012, Polymorphisms of dihydropyrimidine dehydrogenase gene and clinical outcomes of gastric cancer patients treated with fluorouracil-based adjuvant chemotherapy in Chinese population., Chin Med J (Engl)
Deenen MJ et al., 2011, Relationship between single nucleotide polymorphisms and haplotypes in DPYD and toxicity and efficacy of capecitabine in advanced colorectal cancer., Clin Cancer Res
Obi EE et al., 2011, A bilateral cicatricial ectropion and bilateral upper lid shortening caused by 5-fluorouracil toxicity in a patient with dihydropyrimidine dehydrogenase deficiency., Cutan Ocul Toxicol
Kristensen MH et al., 2010, Variants in the dihydropyrimidine dehydrogenase, methylenetetrahydrofolate reductase and thymidylate synthase genes predict early toxicity of 5-fluorouracil in colorectal cancer patients., J Int Med Res
Fariña-Sarasqueta A et al., 2010, Value of gene polymorphisms as markers of 5-FU therapy response in stage III colon carcinoma: a pilot study., Cancer Chemother Pharmacol
Boige V et al., 2010, Pharmacogenetic assessment of toxicity and outcome in patients with metastatic colorectal cancer treated with LV5FU2, FOLFOX, and FOLFIRI: FFCD 2000-05., J Clin Oncol
Braun MS et al., 2009, Association of molecular markers with toxicity outcomes in a randomized trial of chemotherapy for advanced colorectal cancer: the FOCUS trial., J Clin Oncol
Loganayagam A et al., 2010, The contribution of deleterious DPYD gene sequence variants to fluoropyrimidine toxicity in British cancer patients., Cancer Chemother Pharmacol
Amstutz U et al., 2009, Dihydropyrimidine dehydrogenase gene variation and severe 5-fluorouracil toxicity: a haplotype assessment., Pharmacogenomics
Kleibl Z et al., 2009, Influence of dihydropyrimidine dehydrogenase gene (DPYD) coding sequence variants on the development of fluoropyrimidine-related toxicity in patients with high-grade toxicity and patients with excellent tolerance of fluoropyrimidine-based chemotherapy., Neoplasma
van Kuilenburg AB et al., 2008, Pharmacokinetics of 5-fluorouracil in patients heterozygous for the IVS14+1G > A mutation in the dihydropyrimidine dehydrogenase gene., Nucleosides Nucleotides Nucleic Acids
He YF et al., 2008, Analysis of the DPYD gene implicated in 5-fluorouracil catabolism in Chinese cancer patients., J Clin Pharm Ther
Sulzyc-Bielicka V et al., 2008, 5-Fluorouracil toxicity-attributable IVS14 + 1G > A mutation of the dihydropyrimidine dehydrogenase gene in Polish colorectal cancer patients., Pharmacol Rep
Schwab M et al., 2008, Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group., J Clin Oncol
Zhang H et al., 2007, DPYD*5 gene mutation contributes to the reduced DPYD enzyme activity and chemotherapeutic toxicity of 5-FU: results from genotyping study on 75 gastric carcinoma and colon carcinoma patients., Med Oncol
Capitain O et al., 2008, The influence of fluorouracil outcome parameters on tolerance and efficacy in patients with advanced colorectal cancer., Pharmacogenomics J
Cho HJ et al., 2007, Thymidylate synthase (TYMS) and dihydropyrimidine dehydrogenase (DPYD) polymorphisms in the Korean population for prediction of 5-fluorouracil-associated toxicity., Ther Drug Monit
Salgado J et al., 2007, Polymorphisms in the thymidylate synthase and dihydropyrimidine dehydrogenase genes predict response and toxicity to capecitabine-raltitrexed in colorectal cancer., Oncol Rep
Saif MW et al., 2007, DPYD*2A mutation: the most common mutation associated with DPD deficiency., Cancer Chemother Pharmacol
Morel A et al., 2006, Clinical relevance of different dihydropyrimidine dehydrogenase gene single nucleotide polymorphisms on 5-fluorouracil tolerance., Mol Cancer Ther
Boisdron-Celle M et al., 2007, 5-Fluorouracil-related severe toxicity: a comparison of different methods for the pretherapeutic detection of dihydropyrimidine dehydrogenase deficiency., Cancer Lett
Largillier R et al., 2006, Pharmacogenetics of capecitabine in advanced breast cancer patients., Clin Cancer Res
Ezzeldin HH et al., 2005, Methylation of the DPYD promoter: an alternative mechanism for dihydropyrimidine dehydrogenase deficiency in cancer patients., Clin Cancer Res
Al-Sanna'a NA et al., 2005, Dihydropyrimidine dehydrogenase deficiency presenting at birth., J Inherit Metab Dis
Seck K et al., 2005, Analysis of the DPYD gene implicated in 5-fluorouracil catabolism in a cohort of Caucasian individuals., Clin Cancer Res
Takechi T et al., 2005, Correlations between antitumor activities of fluoropyrimidines and DPD activity in lung tumor xenografts., Oncol Rep
Hsiao HH et al., 2004, Dihydropyrimidine dehydrogenase pharmacogenetics in the Taiwanese population., Cancer Chemother Pharmacol
Salgueiro N et al., 2004, Mutations in exon 14 of dihydropyrimidine dehydrogenase and 5-Fluorouracil toxicity in Portuguese colorectal cancer patients., Genet Med
Gross E et al., 2003, Detailed analysis of five mutations in dihydropyrimidine dehydrogenase detected in cancer patients with 5-fluorouracil-related side effects., Hum Mutat
Van Kuilenburg AB et al., 2002, High prevalence of the IVS14 + 1G>A mutation in the dihydropyrimidine dehydrogenase gene of patients with severe 5-fluorouracil-associated toxicity., Pharmacogenetics
Van Kuilenburg AB et al., 2002, Increased risk of grade IV neutropenia after administration of 5-fluorouracil due to a dihydropyrimidine dehydrogenase deficiency: high prevalence of the IVS14+1g>a mutation., Int J Cancer
Johnson MR et al., 2002, Profound dihydropyrimidine dehydrogenase deficiency resulting from a novel compound heterozygote genotype., Clin Cancer Res
Raida M et al., 2001, Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5'-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)- related toxicity compared with controls., Clin Cancer Res
van Kuilenburg AB et al., 2001, Lethal outcome of a patient with a complete dihydropyrimidine dehydrogenase (DPD) deficiency after administration of 5-fluorouracil: frequency of the common IVS14+1G>A mutation causing DPD deficiency., Clin Cancer Res
van Kuilenburg AB et al., 2000, Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: identification of new mutations in the DPD gene., Clin Cancer Res
Collie-Duguid ES et al., 2000, Known variant DPYD alleles do not explain DPD deficiency in cancer patients., Pharmacogenetics
Van Kuilenburg AB et al., 1999, Genotype and phenotype in patients with dihydropyrimidine dehydrogenase deficiency., Hum Genet
Cao et al., 1995, 5-Ethynyluracil (776C85): effects on the antitumor activity and pharmacokinetics of tegafur, a prodrug of 5-fluorouracil., Cancer Res.
Saif et al., 2006, Dihydropyrimidine dehydrogenase deficiency in an Indian population., Cancer Chemother. Pharmacol.
Jakob et al., 2004, Thymidylate synthase, thymidine phosphorylase, dihydropyrimidine dehydrogenase expression, and histological tumour regression after 5-FU-based neo-adjuvant chemoradiotherapy in rectal cancer., J. Pathol.
Araki et al., 2001, Dihydropyrimidine dehydrogenase activity and thymidylate synthase level are associated with response to 5-fluorouracil in human colorectal cancer., Kurume Med J
Hisamitsu et al., Expression of dihydropyrimidine dehydrogenase in cancer cells but not in stromal cells predicts the efficacy of fluorouracil treatment in patients with gastric carcinoma., Anticancer Res.
Ciaparrone et al., 2006, Predictive role of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer patients receiving adjuvant 5-fluorouracil., Oncology
Majounie E et al., 2020, Fluorouracil sensitivity in a head and neck squamous cell carcinoma with a somatic <i>DPYD</i> structural variant., Cold Spring Harb Mol Case Stud
Boisdron-Celle M et al., 2017, A multicenter phase II study of personalized FOLFIRI-cetuximab for safe dose intensification., Semin Oncol
Ichikawa et al., 2003, Combination of dihydropyrimidine dehydrogenase and thymidylate synthase gene expressions in primary tumors as predictive parameters for the efficacy of fluoropyrimidine-based chemotherapy for metastatic colorectal cancer., Clin. Cancer Res.
Ishida et al., 2002, [A case of liver metastasis of rectal cancer demonstrating complete response to 5-FU + Leucovorin + UFT]., Gan To Kagaku Ryoho
Czito et al., 2006, A phase I study of eniluracil/5-FU in combination with radiation therapy for potentially resectable and/or unresectable cancer of the pancreas and distal biliary tract., Cancer Invest.
Leichman et al., 2006, Expression of genes related to activity of oxaliplatin and 5-fluorouracil in endoscopic biopsies of primary esophageal cancer in patients receiving oxaliplatin, 5-flourouracil and radiation: characterization and exploratory analysis with survival., J Chemother

TEGAFUR DPYD

Interaction Score: 130.53

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
9470816 9439663 9323575 32378051 31382864 30858516 30723313 30114658 29889674 29846282 29134491 28950804 28929491 28295243 27995989 27864592 27454530 27122156 26846104 26804652 26794347 26603945 26265035 26216193 26099996 25796495 25677447 25410891 24923815 24817302 23988873 23942539 23930673 23603345 23585145 22490566 21498394 21077799 20819423 20665215 20385995 19858398 19795123 19530960 19473056 18600527 18452418 18443386 18299612 17848752 17700593 17417073 17203168 17165084 17121937 17064846 17000685 16361556 16151913 16115930 15944764 15132136 15017333 14635116 12360106 12209976 11895907 11555601 11350878 11156223 10803677 10071185 8521418

Sources:
NCI CIViC PharmGKB
ENILURACIL DPYD

Interaction Score: 10.3

Interaction Types & Directionality:

n/a

Interaction Info:

Trial Name eniluracil

Novel drug target Novel Target

PMIDs:
16466986

Sources:
TdgClinicalTrial TTD
GIMERACIL DPYD

Interaction Score: 6.87

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name S-1, TS1

Novel drug target Novel Target

PMIDs:
None found

Sources:
TdgClinicalTrial
FLUCYTOSINE DPYD

Interaction Score: 3.43

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
LEUCOVORIN DPYD

Interaction Score: 1.47

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
12576451 11977552 31871216

Sources:
NCI CIViC PharmGKB
CAPECITABINE DPYD

Interaction Score: 0.95

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16279094 23988873

Sources:
NCI CIViC FDA
FLUOROURACIL DPYD

Interaction Score: 0.72

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16421754 15538739 11501504 15330204 17179731 31871216 23988873

Sources:
NCI CIViC TTD FDA
OXALIPLATIN DPYD

Interaction Score: 0.37

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
17127229

Sources:
NCI
IRINOTECAN DPYD

Interaction Score: 0.26

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
28395759

Sources:
PharmGKB

Ensembl: ENSG00000188641
- Version: 101_38
Alternate Names:

DPYD Ensembl Gene Name

Gene Info:

Gene Biotype PROTEIN_CODING

Publications:
TdgClinicalTrial: Q12882
- Version: January-2014
Alternate Names:

DPYD Gene Symbol

Gene Info:

Target Class Enzymes

Target Subclass EC:1.3.1.2

Publications:

RussLampel: ENSG00000188641

Version: 26-July-2011

Alternate Names:

ENSG00000188641 Ensembl Gene Id

DIHYDROPYRIMIDINE DEHYDROGENASE [NADP+] PRECURSOR (EC 1.3.1.2) (DPD) (DHPDHASE) (DIHYDROURACIL DEHYDROGENASE) (DIHYDROTHYMINE DEHYDROGENASE). [SOURCE:UNIPROT/SWISSPROT;ACC:Q12882] Description

DPYD Display Id

Gene Info:

Human Readable Name DRUGGABLE GENOME

Gene Categories:

DRUGGABLE GENOME

Publications:

PharmGKB: DPYD

Version: 18-August-2020

Alternate Names:

PA145 PharmGKB ID

Gene Info:

Publications:

Van Kuilenburg AB et al., 2002, Increased risk of grade IV neutropenia after administration of 5-fluorouracil due to a dihydropyrimidine dehydrogenase deficiency: high prevalence of the IVS14+1g>a mutation., Int J Cancer

Zurayk M et al., 2019, Successful use of uridine triacetate (Vistogard) three weeks after capecitabine in a patient with homozygous dihydropyrimidine dehydrogenase mutation: A case report and review of the literature., J Oncol Pharm Pract

Froehlich TK et al., 2015, Clinical importance of risk variants in the dihydropyrimidine dehydrogenase gene for the prediction of early-onset fluoropyrimidine toxicity., Int J Cancer

CIViC: DPYD

Version: 14-September-2020

Alternate Names:

1806 Entrez Gene ID

1526 CIViC Gene ID

Gene Info:

Gene Categories:

CLINICALLY ACTIONABLE

Publications:

Caudle et al., 2013, Clinical Pharmacogenetics Implementation Consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing., Clin. Pharmacol. Ther.

Majounie E et al., 2020, Fluorouracil sensitivity in a head and neck squamous cell carcinoma with a somatic <i>DPYD</i> structural variant., Cold Spring Harb Mol Case Stud

NCI: DPYD

Version: 14-September-2017

Alternate Names:

Gene Info:

Publications:

Ciaparrone et al., 2006, Predictive role of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer patients receiving adjuvant 5-fluorouracil., Oncology

Araki et al., 2001, Dihydropyrimidine dehydrogenase activity and thymidylate synthase level are associated with response to 5-fluorouracil in human colorectal cancer., Kurume Med J

Cao et al., 1995, 5-Ethynyluracil (776C85): effects on the antitumor activity and pharmacokinetics of tegafur, a prodrug of 5-fluorouracil., Cancer Res.

HingoraniCasas: ENSG00000188641
- Version: 31-May-2017
Alternate Names:

ENSG00000188641 Gene Symbol

DPYD Ensembl Id

Gene Info:

Gene Categories:

DRUGGABLE GENOME

Publications:
Tempus: DPYD
- Version: 11-November-2018
Alternate Names:

DPYD Gene Symbol

Gene Info:

Gene Categories:

CLINICALLY ACTIONABLE

Publications:
TTD: Dihydrothymine dehydrogenase
- Version: 2020.06.01
Alternate Names:

DPYD TTD Gene Abbreviation

T75890 TTD Target ID

Gene Info:

Publications:
Pharos: DPYD
- Version: 01-February-2022
Alternate Names:

Dihydropyrimidine dehydrogenase [NADP(+)] Gene Name

Q12882 UniProt ID

Gene Info:

Gene Categories:

ENZYME

Publications:
FDA: DPYD
- Version: 04-September-2020
Alternate Names:

Gene Info:

Publications:

ENSG00000188641	Ensembl Gene Id
DIHYDROPYRIMIDINE DEHYDROGENASE [NADP+] PRECURSOR (EC 1.3.1.2) (DPD) (DHPDHASE) (DIHYDROURACIL DEHYDROGENASE) (DIHYDROTHYMINE DEHYDROGENASE). [SOURCE:UNIPROT/SWISSPROT;ACC:Q12882]	Description
DPYD	Display Id

Dihydropyrimidine dehydrogenase [NADP(+)]	Gene Name
Q12882	UniProt ID

Trial Name	eniluracil
Novel drug target	Novel Target

Trial Name	S-1, TS1
Novel drug target	Novel Target

DPYD Gene Record

DPYD 1806 Druggable GenomeClinically Actionable

Alternate Names:

Gene Info:

Gene Categories: Category Details

Publications:

Interaction Types & Directionality: n/a

Interaction Info:

Sources: NCI CIViC PharmGKB

Interaction Types & Directionality: n/a

Interaction Info: Trial Name eniluracil Novel drug target Novel Target

PMIDs: 16466986

Sources: TdgClinicalTrial TTD

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Trial Name S-1, TS1 Novel drug target Novel Target

PMIDs: None found

Sources: TdgClinicalTrial

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 12576451 11977552 31871216

Sources: NCI CIViC PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 16279094 23988873

Sources: NCI CIViC FDA

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 16421754 15538739 11501504 15330204 17179731 31871216 23988873

Sources: NCI CIViC TTD FDA

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 17127229

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 28395759

Sources: PharmGKB

Ensembl: ENSG00000188641

Alternate Names: DPYD Ensembl Gene Name

Gene Info: Gene Biotype PROTEIN_CODING

Publications:

TdgClinicalTrial: Q12882

Alternate Names: DPYD Gene Symbol

Gene Info: Target Class Enzymes Target Subclass EC:1.3.1.2

Publications:

RussLampel: ENSG00000188641

Alternate Names: ENSG00000188641 Ensembl Gene Id DIHYDROPYRIMIDINE DEHYDROGENASE [NADP+] PRECURSOR (EC 1.3.1.2) (DPD) (DHPDHASE) (DIHYDROURACIL DEHYDROGENASE) (DIHYDROTHYMINE DEHYDROGENASE). [SOURCE:UNIPROT/SWISSPROT;ACC:Q12882] Description DPYD Display Id

Gene Info: Human Readable Name DRUGGABLE GENOME

Gene Categories: DRUGGABLE GENOME

Publications:

PharmGKB: DPYD

Alternate Names: PA145 PharmGKB ID

Gene Info:

CIViC: DPYD

Alternate Names: 1806 Entrez Gene ID 1526 CIViC Gene ID

Gene Info:

Gene Categories: CLINICALLY ACTIONABLE

NCI: DPYD

Alternate Names:

Gene Info:

HingoraniCasas: ENSG00000188641

Alternate Names: ENSG00000188641 Gene Symbol DPYD Ensembl Id

Gene Info:

Gene Categories: DRUGGABLE GENOME

Publications:

Tempus: DPYD

Alternate Names: DPYD Gene Symbol

Gene Info:

Gene Categories: CLINICALLY ACTIONABLE

Publications:

TTD: Dihydrothymine dehydrogenase

Alternate Names: DPYD TTD Gene Abbreviation T75890 TTD Target ID

Gene Info:

Publications:

Pharos: DPYD

Alternate Names: Dihydropyrimidine dehydrogenase [NADP(+)] Gene Name Q12882 UniProt ID

Interaction Types & Directionality:

n/a

Sources:
NCI CIViC PharmGKB

Interaction Types & Directionality:

n/a

Interaction Info:

Trial Name eniluracil

Novel drug target Novel Target

PMIDs:
16466986

Sources:
TdgClinicalTrial TTD

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name S-1, TS1

Novel drug target Novel Target

PMIDs:
None found

Sources:
TdgClinicalTrial

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
12576451 11977552 31871216

Sources:
NCI CIViC PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
16279094 23988873

Sources:
NCI CIViC FDA

Interaction Types & Directionality:

n/a

PMIDs:
16421754 15538739 11501504 15330204 17179731 31871216 23988873

Sources:
NCI CIViC TTD FDA

Interaction Types & Directionality:

n/a

PMIDs:
17127229

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
28395759

Sources:
PharmGKB

Alternate Names:

DPYD Ensembl Gene Name

Gene Info:

Gene Biotype PROTEIN_CODING

Alternate Names:

DPYD Gene Symbol

Gene Info:

Target Class Enzymes

Target Subclass EC:1.3.1.2

Alternate Names:

ENSG00000188641 Ensembl Gene Id

DIHYDROPYRIMIDINE DEHYDROGENASE [NADP+] PRECURSOR (EC 1.3.1.2) (DPD) (DHPDHASE) (DIHYDROURACIL DEHYDROGENASE) (DIHYDROTHYMINE DEHYDROGENASE). [SOURCE:UNIPROT/SWISSPROT;ACC:Q12882] Description

DPYD Display Id

Gene Info:

Human Readable Name DRUGGABLE GENOME

Gene Categories:

DRUGGABLE GENOME

Alternate Names:

PA145 PharmGKB ID

Alternate Names:

1806 Entrez Gene ID

1526 CIViC Gene ID

Gene Categories:

CLINICALLY ACTIONABLE

Alternate Names:

ENSG00000188641 Gene Symbol

DPYD Ensembl Id

Gene Categories:

DRUGGABLE GENOME

Alternate Names:

DPYD Gene Symbol

Gene Categories:

CLINICALLY ACTIONABLE

Alternate Names:

DPYD TTD Gene Abbreviation

T75890 TTD Target ID

Alternate Names:

Dihydropyrimidine dehydrogenase [NADP(+)] Gene Name

Q12882 UniProt ID

Gene Categories:

ENZYME